These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 20420444)

  • 1. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
    Liu H; Yao X; Wang C; Han J
    Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
    Wang YT; Chan CH; Su ZY; Chen CL
    Biophys Chem; 2010 Mar; 147(1-2):74-80. PubMed ID: 20045243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.
    Li L; Li Y; Zhang L; Hou T
    J Chem Inf Model; 2012 Oct; 52(10):2715-29. PubMed ID: 22998323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P; Li L; Li Y; Li D; Hou T
    Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
    Park JW; Jo WH
    J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
    Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
    Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
    Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
    Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexity in influenza virus targeted drug design: interaction with human sialidases.
    Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
    J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
    Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
    Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
    Magano J
    Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
    [No Abstract]   [Full Text] [Related]  

  • 16. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM
    Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.
    Carbain B; Martin SR; Collins PJ; Hitchcock PB; Streicher H
    Org Biomol Chem; 2009 Jun; 7(12):2570-5. PubMed ID: 19503932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
    Karthick V; Shanthi V; Rajasekaran R; Ramanathan K
    Appl Biochem Biotechnol; 2012 May; 167(2):237-49. PubMed ID: 22544690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus.
    Rungrotmongkol T; Intharathep P; Malaisree M; Nunthaboot N; Kaiyawet N; Sompornpisut P; Payungporn S; Poovorawan Y; Hannongbua S
    Biochem Biophys Res Commun; 2009 Jul; 385(3):390-4. PubMed ID: 19463784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.